Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 180 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate to Severe Ulcerative Colitis Clear all
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 27, 2026, 4:32 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 27, 2026, 4:32 AM EDT
Terminated Phase 2Phase 3 Interventional

Hyperbaric Oxygen for Ulcerative Colitis

NCT02144350
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hyperbaric oxygen, Sham Hyperbaric Air
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Rochester, Minnesota • Lebanon, New Hampshire • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

NCT05507216
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
16 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
61
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 27, 2026, 4:32 AM EDT
Active, not recruiting Phase 2 Interventional

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
SAR443122, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Lancaster, California • Atlanta, Georgia • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 27, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05672199
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Efavaleukin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Santa Maria, California • Kissimmee, Florida • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

NCT03029143
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
44
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Pablo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab IV, placebo for risankizumab, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
82
States / cities
Coronado, California • Irvine, California • La Jolla, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Jun 27, 2026, 4:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
18
States / cities
San Diego, California • Kissimmee, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 27, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

NCT02895100
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PTG-100, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Los Angeles, California • Colorado Springs, Colorado • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

NCT02447302
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Dothan, Alabama • Thousand Oaks, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Jun 27, 2026, 4:32 AM EDT
Recruiting Phase 2 Interventional

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tilpisertib Fosmecarbil, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
53
States / cities
Sun City, Arizona • Chula Vista, California • Coronado, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

NCT02840721
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
PF-06480605
Drug
Lead sponsor
Telavant, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Aventura, Florida • North Miami Beach, Florida • Pembroke Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

NCT01647516
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 73 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
10
States / cities
Anaheim, California • La Jolla, California • Oceanside, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 27, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

NCT03298022
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-168
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Newport Beach, California • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

NCT02435992
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RPC1063, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
113
States / cities
Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

NCT05291689
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions
MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Tampa, Florida • Lafayette, Louisiana • Freehold, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 27, 2026, 4:32 AM EDT
Active, not recruiting No phase listed Observational

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
8,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
169
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jun 27, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT03650413
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jun 27, 2026, 4:32 AM EDT
Terminated Phase 3 Interventional

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo
Drug
Lead sponsor
InDex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Jun 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

NCT02589665
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Chula Vista, California • La Jolla, California • Rialto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jun 27, 2026, 4:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 27, 2026, 4:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT03167437
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vorinostat, Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 27, 2026, 4:32 AM EDT